{"id":66222,"date":"2026-05-25T22:01:44","date_gmt":"2026-05-25T14:01:44","guid":{"rendered":"https:\/\/flcube.com\/?p=66222"},"modified":"2026-05-25T22:01:45","modified_gmt":"2026-05-25T14:01:45","slug":"gilead-sciences-secures-fda-accelerated-approval-for-hepcludex-as-first-us-treatment-for-hepatitis-delta-virus","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66222","title":{"rendered":"Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>U.S. Food and Drug Administration (FDA)<\/strong> granted <strong>accelerated approval<\/strong> to <strong>Gilead Sciences, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ: GILD<\/a>)<\/strong> for <strong>Hepcludex (bulevirtide) 8.5 mg<\/strong>, marking the <strong>first and only approved treatment<\/strong> for <strong>chronic hepatitis delta virus (HDV) infection<\/strong> in the United States.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-details\" class=\"wp-block-heading\">Regulatory Approval Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Name<\/strong><\/td><td>Hepcludex (bulevirtide) 8.5 mg<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Chronic hepatitis delta virus (HDV) infection in adults<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Accelerated approval<\/td><\/tr><tr><td><strong>Approval Status<\/strong><\/td><td>First and only HDV treatment approved in the US<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Gilead Sciences, Inc. (NASDAQ: GILD)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-basis-amp-efficacy-data\" class=\"wp-block-heading\">Clinical Basis &amp; Efficacy Data<\/h2>\n\n\n\n<h3 id=\"h-phase-iii-myr301-study-results\" class=\"wp-block-heading\">Phase III MYR301 Study Results<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Study Design:<\/strong> Phase III randomized controlled trial with delayed-treatment control group<\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> Combined virologic and biochemical response at week 48<\/li>\n\n\n\n<li><strong>Key Finding:<\/strong> Statistically significant improvements in combined endpoints vs. control group<\/li>\n\n\n\n<li><strong>Clinical Outcomes:<\/strong> Efficacy in improving disease-related clinical outcomes not yet established (required for full approval)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-disease-context-amp-unmet-need\" class=\"wp-block-heading\">Disease Context &amp; Unmet Need<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Severity:<\/strong> Chronic hepatitis delta is considered the <strong>most severe form of viral hepatitis<\/strong><\/li>\n\n\n\n<li><strong>Disease Progression:<\/strong> Significantly higher risk of rapid progression, liver failure, and death compared to HBV alone<\/li>\n\n\n\n<li><strong>US Patient Population:<\/strong> Estimated <strong>40,000 to 80,000 individuals<\/strong> affected (2-4% of chronic HBV patients)<\/li>\n\n\n\n<li><strong>Previous Treatment Options:<\/strong> No approved therapies existed prior to Hepcludex approval<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-mechanism-of-action-amp-therapeutic-approach\" class=\"wp-block-heading\">Mechanism of Action &amp; Therapeutic Approach<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Hepcludex represents a novel therapeutic approach targeting the unique biology of HDV:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Target:<\/strong> Entry inhibitor that blocks HDV&#8217;s ability to infect hepatocytes<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> HDV requires hepatitis B surface antigen (HBsAg) for viral assembly and propagation<\/li>\n\n\n\n<li><strong>Treatment Strategy:<\/strong> Addresses the critical unmet need in a patient population with limited therapeutic options and poor prognosis<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-implications-amp-commercial-outlook\" class=\"wp-block-heading\">Market Implications &amp; Commercial Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The accelerated approval positions Gilead as the pioneer in HDV therapeutics, creating a first-mover advantage in a niche but high-need market segment. With an estimated <strong>40,000-80,000 US patients<\/strong> and significantly worse outcomes than HBV monoinfection, Hepcludex addresses a substantial unmet medical need.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">However, the <strong>accelerated approval pathway<\/strong> requires Gilead to conduct additional confirmatory trials demonstrating clinical benefit to convert to full approval. This creates both opportunity and risk, as the company must validate meaningful improvements in hard clinical endpoints such as liver-related mortality, transplantation rates, or decompensation events.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The approval also strengthens Gilead&#8217;s position in viral hepatitis therapeutics, complementing its established portfolio in HBV and HCV treatments. The company&#8217;s expertise in liver disease and antiviral development provides strategic advantages in commercializing this specialized therapy.<\/p>\n\n\n\n<h2 id=\"h-global-context-amp-future-development\" class=\"wp-block-heading\">Global Context &amp; Future Development<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">While Hepcludex is now approved in the US, it has previously received conditional marketing authorization in the European Union. Gilead&#8217;s global development strategy reflects the international nature of HDV, which affects an estimated <strong>12-72 million people worldwide<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company will likely focus on specialized hepatology centers and academic medical institutions for initial market penetration, given the complexity of HDV diagnosis and management.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ due to risks including requirements for confirmatory trials, market adoption, pricing negotiations, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) granted accelerated approval to Gilead Sciences, Inc. (NASDAQ:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[226,1025,15,89],"class_list":["post-66222","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-gilead-sciences","tag-nasdaq-gild","tag-product-approvals","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. Food and Drug Administration (FDA) granted accelerated approval to Gilead Sciences, Inc. (NASDAQ: GILD) for Hepcludex (bulevirtide) 8.5 mg, marking the first and only approved treatment for chronic hepatitis delta virus (HDV) infection in the United States.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66222\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration (FDA) granted accelerated approval to Gilead Sciences, Inc. (NASDAQ: GILD) for Hepcludex (bulevirtide) 8.5 mg, marking the first and only approved treatment for chronic hepatitis delta virus (HDV) infection in the United States.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66222\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-25T14:01:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-25T14:01:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66222#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66222\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus\",\"datePublished\":\"2026-05-25T14:01:44+00:00\",\"dateModified\":\"2026-05-25T14:01:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66222\"},\"wordCount\":517,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Gilead Sciences\",\"NASDAQ: GILD\",\"Product approvals\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66222#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66222\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66222\",\"name\":\"Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-25T14:01:44+00:00\",\"dateModified\":\"2026-05-25T14:01:45+00:00\",\"description\":\"The U.S. Food and Drug Administration (FDA) granted accelerated approval to Gilead Sciences, Inc. (NASDAQ: GILD) for Hepcludex (bulevirtide) 8.5 mg, marking the first and only approved treatment for chronic hepatitis delta virus (HDV) infection in the United States.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66222#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66222\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66222#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus - Insight, China&#039;s Pharmaceutical Industry","description":"The U.S. Food and Drug Administration (FDA) granted accelerated approval to Gilead Sciences, Inc. (NASDAQ: GILD) for Hepcludex (bulevirtide) 8.5 mg, marking the first and only approved treatment for chronic hepatitis delta virus (HDV) infection in the United States.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66222","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus","og_description":"The U.S. Food and Drug Administration (FDA) granted accelerated approval to Gilead Sciences, Inc. (NASDAQ: GILD) for Hepcludex (bulevirtide) 8.5 mg, marking the first and only approved treatment for chronic hepatitis delta virus (HDV) infection in the United States.","og_url":"https:\/\/flcube.com\/?p=66222","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-25T14:01:44+00:00","article_modified_time":"2026-05-25T14:01:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66222#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66222"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus","datePublished":"2026-05-25T14:01:44+00:00","dateModified":"2026-05-25T14:01:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66222"},"wordCount":517,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Gilead Sciences","NASDAQ: GILD","Product approvals","Viral hepatitis"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66222#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66222","url":"https:\/\/flcube.com\/?p=66222","name":"Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-25T14:01:44+00:00","dateModified":"2026-05-25T14:01:45+00:00","description":"The U.S. Food and Drug Administration (FDA) granted accelerated approval to Gilead Sciences, Inc. (NASDAQ: GILD) for Hepcludex (bulevirtide) 8.5 mg, marking the first and only approved treatment for chronic hepatitis delta virus (HDV) infection in the United States.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66222#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66222"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66222#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66222"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66222\/revisions"}],"predecessor-version":[{"id":66223,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66222\/revisions\/66223"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}